IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in 1q21(amp) multiple myeloma.
1q21 amplification (1q21(amp)) is an important prognostic marker in multiple myeloma. Herein, we identified that IL6R (IL6 membrane receptor) and ADAR1 (RNA editing enzyme) are critical genes located within the minimally amplified 1q21 region. Loss of individual gene caused suppression to the oncogenic phenotypes, the magnitude of which was enhanced when both genes were concomitantly lost. Mechanistically, IL6R and ADAR1 collaborated to induce a hyperactivation of the oncogenic STAT3 pathway. High IL6R confers hypersensitivity to IL6 binding, whereas, ADAR1 forms a constitutive feed-forward loop with STAT3 in a P150-isoform-predominant manner. In this respect, ADAR1-P150 acts as a direct transcriptional target for STAT3 and this STAT3-induced-P150 in turn directly interacts with and stabilizes the former protein, leading to more protein pool acting as oncogenic transcription factors for pro-survival genes. The importance of both IL6R and ADAR1-P150 in the STAT3 signaling was further validated when knockdown of both genes impeded IL6-induced-STAT3 pathway activation. Clinical evaluation of various myeloma patient datasets showed that low expression of either one or both genes was closely associated with compromised STAT3 signature, confirming the involvement of IL6R and ADAR1 in STAT3 pathway and underscoring their essential role in disease pathogenesis. In summary, our findings highlight the complexity of STAT3 pathway in myeloma, in association with 1q21(amp). This study therefore provides a novel perspective of 1q21 abnormalities in myeloma and the potential therapeutic means for this cohort of high-risk patients.